Highlights

  • Cogstate (ASX:CGS) signed US$25.13 million in net sales contracts in the September 2026 quarter.
  • Contracted FY27 revenue reached US$56.8 million at 30 September 2026, up 45% on the corresponding measure.
  • Total contracted revenue of US$143.7 million was 41% higher than the comparable year-earlier figure.
  • FY26 revenue was US$60.86 million, with net profit after tax of approximately US$11.9 million.

Cogstate Limited develops digital cognitive assessments and provides clinical trial services designed to measure neurological and psychiatric outcomes. Its October 2026 business update reported new contracts in mood-disorder studies and an expanded contracted revenue pipeline for FY27 and subsequent years. Delivery of contracted studies, including several longer-duration Phase 3 programs, is central to the company’s near-term operating profile.

Company Business

Cogstate (ASX:CGS) supplies cognitive assessment technology and related scientific and operational services to pharmaceutical sponsors and clinical research organisations. Its work is concentrated on central nervous system research, where consistent cognitive testing and clinical endpoint quality can be important for evaluating treatments. The business provides digital assessments, study design support, training and oversight aimed at improving the consistency of measurements across research sites.

The company serves clinical trials across multiple neurological and psychiatric indications. Alzheimer’s disease research remains part of its addressable market, while projects in depression, bipolar disorder and other conditions broaden the mix of studies. Global trial delivery also requires coordination across languages, locations and technology systems. Cogstate’s channel approach allows customers to use preferred clinical data capture providers while retaining its specialist assessment and endpoint services.

Recent Development

In its 12 October 2026 update, Cogstate (ASX:CGS) reported US$25.13 million of net sales contracts executed in the first quarter of FY27, compared with US$21.42 million in the September 2025 quarter. New Phase 3 mood-disorder programs were particularly significant: five trials spanning bipolar disorder or depression, across two customers, accounted for more than 80% of the quarter’s contracted sales value.

The company said its channel partnership strategy contributed to these awards by allowing sponsors to retain their preferred technology providers. Such contracts can support contracted revenue over several reporting periods, rather than producing an immediate equivalent increase in recognised revenue. The September-quarter sales had a 34% in-year FY27 revenue yield. Licence fees represented 7% of the new contract value, below the company’s stated historical range of 20%–25%, while longer Phase 3 trial timelines also affected the recognition profile.

At 30 September, contracted FY27 revenue stood at US$56.8 million, compared with US$48.3 million three months earlier. The update reported US$39.7 million of FY28 contracted revenue, up from US$31.4 million at 30 June. Together, those changes increased visibility of future contracted work, subject to trials proceeding as scheduled.

Financial Performance and Sector Context

Cogstate (ASX:CGS) reported revenue of US$60.86 million for the financial year ended 30 June 2026, an increase of approximately 15% from FY25. Net profit after tax was about US$11.9 million, up approximately 17%, while profit before tax was US$16.1 million. The company executed US$89.0 million of sales contracts during FY26, more than twice the previous year’s US$41.26 million.

At 30 September 2026, Cogstate reported aggregate contracted revenue of US$143.7 million, compared with US$101.8 million on the corresponding prior-year basis. Of this total, US$31.7 million related to the first half of FY27, US$56.8 million to FY27 as a whole, and US$86.9 million to FY28–FY33. These are contracted amounts, not revenue recognised in the quarter; contract duration, licence mix and timing influence when sales flow through the income statement.

Central nervous system research presents specialist scientific and operational challenges, including participant variability and the need for repeatable assessments. Demand for the company’s services therefore depends partly on clinical development budgets, the progression of sponsor programs and the selection of external service providers.

Risks to Consider

Cogstate (ASX:CGS) is exposed to clinical trial postponements, changes in study design, sponsor funding decisions and cancellations. Concentration of quarterly new-contract value in a small number of Phase 3 programs can make bookings variable. Longer projects also defer portions of recognised revenue, so growth in contracted work need not correspond to immediate earnings growth. Delivery quality, staffing, data security and competing assessment technologies remain operating considerations.

What to Watch Next

Future reporting will show whether new sales continue across indications and how contracted programs convert into recognised FY27 revenue. Key indicators include contract execution, first-half revenue recognition against the US$31.7 million contracted figure, the revenue mix of licence fees versus longer-running services, and movements in the FY28 pipeline. Updates on channel partnerships, clinical study starts and operating expenditure will also help explain margins and cash generation.

Key Insights

Cogstate (ASX:CGS) entered FY27 with higher contracted revenue than a year earlier and secured additional Phase 3 work in mood disorders during the September quarter. FY26 reported revenue and earnings increased, although the timing of revenue conversion remains dependent on study schedules and contract mix. Subsequent disclosures on trial execution, contracted sales and recognised income will clarify how the expanded pipeline translates into reported financial performance.